牙周炎治疗对2型糖尿病患者的全身效应:一项为期12个月的单中心、研究者设盲、随机试验
这项为期12个月的单中心、平行组、研究者设盲随机试验纳入264例伴中重度牙周炎的2型糖尿病患者,比较强化牙周治疗(IPT)与对照牙周治疗(CPT)。结果提示常规口腔健康评估和治疗牙周炎可能对2型糖尿病管理重要。
要点
- 伴中重度牙周炎的2型糖尿病患者接受强化牙周治疗12个月后HbA1c更低。
- 建议将常规口腔健康评估和牙周炎治疗纳入糖尿病管理。
核心结论
- 与CPT相比,IPT在12个月时降低了伴中重度牙周炎的2型糖尿病患者的HbA1c。
- 结果提示常规口腔健康评估和治疗牙周炎可能对2型糖尿病有效管理重要。
研究设计与样本
- 为期12个月、单中心、平行组、研究者设盲的随机试验。
- 从英国四家当地医院及15家医疗或牙科诊所招募伴中重度牙周炎且至少有15颗牙的2型糖尿病患者。
- 按1:1随机分配接受IPT或CPT,共264例纳入意向性治疗分析(IPT组133例,CPT组131例)。
- 主要结局为意向性治疗人群12个月时HbA1c的组间差异。
主要发现
- IPT组30例(23%)报告至少一次不良事件,CPT组23例(18%);严重不良事件分别为11例(8%,含1例死亡)和11例(8%,含3例死亡)。
临床怎么用
- 对伴中重度牙周炎的2型糖尿病患者,可考虑进行常规口腔健康评估并治疗牙周炎以辅助血糖管理。
局限性
- 单中心设计可能限制结果的外推性。
- 研究纳入伴中重度牙周炎且至少有15颗牙的特定2型糖尿病人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic inflammation is believed to be a major mechanism underlying the pathophysiology of type 2 diabetes. Periodontitis is a cause of systemic inflammation. We aimed to assess the effects of periodontal treatment on glycaemic control in people with type 2 diabetes. METHODS: In this 12 month, single-centre, parallel-group, investigator-masked, randomised trial, we recruited patients with type 2 diabetes, moderate-to-severe periodontitis, and at least 15 teeth from four local hospitals and 15 medical or dental practices in the UK. We randomly assigned patients (1:1) using a computer-generated table to receive intensive periodontal treatment (IPT; whole mouth subgingival scaling, surgical periodontal therapy [if the participants showed good oral hygiene practice; otherwise dental cleaning again], and supportive periodontal therapy every 3 months until completion of the study) or control periodontal treatment (CPT; supra-gingival scaling and polishing at the same timepoints as in the IPT group). Treatment allocation included a process of minimisation in terms of diabetes onset, smoking status, sex, and periodontitis severity. Allocation to treatment was concealed in an opaque envelope and revealed to the clinician on the day of first treatment. With the exception of dental staff who performed the treatment and clinical examinations, all study investigators were masked to group allocation. The primary outcome was between-group difference in HbA1c at 12 months in the intention-to-treat population. This study is registered with the ISRCTN registry, number ISRCTN83229304. FINDINGS: Between Oct 1, 2008, and Oct 31, 2012, we randomly assigned 264 patients to IPT (n=133) or CPT (n=131), all of whom were included in the intention-to-treat population. At baseline, mean HbA1c was 8·1% (SD 1·7) in both groups. After 12 months, unadjusted mean HbA1c was 8·3% (SE 0·2) in the CPT group and 7·8% (0·2) in the IPT group; with adjustment for baseline HbA1c, age, sex, ethnicity, smoking status, duration of diabetes, and BMI, HbA1c was 0·6% (95% CI 0·3-0·9; p<0·0001) lower in the IPT group than in the CPT group. At least one adverse event was reported in 30 (23%) of 133 patients in the IPT group and 23 (18%) of 131 patients in the CPT group. Serious adverse events were reported in 11 (8%) patients in the IPT group, including one (1%) death, and 11 (8%) patients in the CPT group, including three (2%) deaths. INTERPRETATION: Compared with CPT, IPT reduced HbA1c in patients with type 2 diabetes and moderate-to-severe periodontitis after 12 months. These results suggest that routine oral health assessment and treatment of periodontitis could be important for effective management of type 2 diabetes. FUNDING: Diabetes UK and UK National Institute for Health Research.
引用
- D'Aiuto F, Gkranias N, Bhowruth D, et al. Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. Lancet Diabetes Endocrinol. 2018. PMID: 30472992. doi:10.1016/S2213-8587(18)30038-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。